Amgen's skin cancer drug hits main goal in late-stage trial

03/20/2013 | Reuters

Sixteen percent of patients who took Amgen's experimental advanced melanoma drug talimogene laherparepvec experienced at least partial tumor shrinkage for six months, compared with 2% of patients who received subcutaneous granulocyte-macrophage colony-stimulating factor, preliminary data from a late-stage trial showed. A detailed look at the study is set for release at a medical meeting this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC